IRVINE, Calif., Sept. 19, 2006 (PRIMEZONE) -- "With a target as large as the multi-billion dollar pharmaceutical industry, companies are employing creative means to capitalize on opportunities beyond traditional sales that can quickly move them into high-growth market segments," stated SmallCap Sentinel analyst, D.R. Clark. "By effectively integrating marketing strategies, companies that acquire existing and profitable brands can take advantage of proven distribution and sales structures put in place for other products," added Clark.
"For example, Auriga Laboratories(tm), Inc. (OTCBB:ARGA) announced today that it had acquired an exclusive license to market FDA-cleared Aquoral(tm), a prescription-only product designed to treat Xerostomia, a condition characterized by a lack of saliva in the mouth. Xerostomia is a common side-effect of many prescription drugs as well as many medical treatments and represents a potential marketplace estimated at more than $1 billion," Clark added.
"Saliva contains components of the immune system that fight bacteria and disease while maintaining the health of teeth and gums. Enzymes and lubricants in saliva begin the process of digestion of food before swallowing. Saliva is an important component in our bodies and the loss of it is difficult to treat," said Clark.
Auriga Laboratories, Inc., a specialty pharmaceutical company, engages in the development and marketing of prescription products for drugs using drug-delivery technologies and reformulation strategies. It offers Extendryl(r) and Levall, prescription cough/cold/respiratory, medication product lines. Auriga Laboratories' products address disease treatment in various areas, such as cold medications, gastrointestinal disorders, and central nervous system disorders.
The report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is available via StockUpTicks.com at www.SmallCapSentinel.com
The report details issues affecting the current market for biotechnology and pharmaceutical companies including Baxter International Inc. (NYSE:BAX), Intuitive Surgical Inc. (Nasdaq:ISRG), ev3, Inc. (Nasdaq:EVVV) and Auriga Laboratories.
Individuals may also register for future reports at: http://stockupticks.com/register.html. To have your company featured in StockUpTicks or SmallCap Sentinel please contact us at sts@marketpathways.com or the number below.
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities but is rather a paid advertisement provided for information purposes only and shouldn't be used as basis for any investment decision. MP isn't an investment advisor and this report isn't investment advice. MP has been paid $1,500 by Auriga Laboratories for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in communication regarding the subject companies.